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Abstract
Background—This study tested the hypothesis that docetaxel confers a greater advantage over
anthracyclines in p53 mutant compared to p53 wild type breast cancers.
Methods—Patients with locally advanced, inflammatory or large operable breast cancers were
randomised to receive neoadjuvant chemotherapy consisting of either a standard anthracycline
regimen (FEC 100 or tailored FEC) or a taxane-based regimen (docetaxel for 3 cycles, followed
by epirubicin and docetaxel for 3 cycles). In this open label study, randomisation was performed
using a minimisation method that stratified by institution and initial tumour stage (large operable
versus locally advanced or inflammatory breast cancer). p53 status was assessed with a yeast
functional assay on tumour biopsies taken before chemotherapy. The primary endpoint was a
comparison of progression-free survival in the two arms according to p53 status and in the entire
trial population (by intention to treat). We report the final analysis of the trial. The study is
registered in ClinicalTrials.gov, number NCT00017095.
Findings—1856 patients were enrolled and 370 were unassessable for p53 tumour status (the
main reason being low tumour cell content in the biopsy). 675 events for the primary endpoint
were registered. The hazard ratio (HR) between the two arms for progression-free survival (PFS)
was 0.84 (98% CI: 0.63–1.14; p=0.17) in the p53 mutant group and 0.89 (98% CI: 0.68–1.18;
p=0.35) in the p53 wild type group. In the entire population, the HR was 0.85 (98% CI: 0.71–1.02;
p=0.035) for the use of docetaxel. The most common grade 3 or 4 adverse events were
neutropenia in 1598 patients (86.6%), febrile neutropenia in 284 (15.4%), fatigue in 136 (7.4%),
infection in 121 (6.6%) and nausea or vomiting in 89 (4.8%). Two patients died of toxicity during
or within 30 days of chemotherapy completion and without disease relapse (one in each arm).
Interpretation—Although p53 status is prognostic for overall survival, it was not predictive of
preferential sensitivity to taxanes. p53 status tested by yeast assay in this population can not be
used to select patients for FEC versus taxane-based chemotherapy.
Funding—National Cancer Institute (USA), “La Ligue Nationale Contre le Cancer”, EU (fp6
Active p53 grant), Pharmacia and Sanofi-Aventis.
Introduction
One consequence of the revolution in genomics is that matching treatments to genotypes
will play an increasing role in modern drug development. Most classic cytotoxic drugs were
developed before the causal oncogenic mutations in tumours were known. Since the proteins
these drugs target are not mutant in tumours, it is difficult to predict individual
chemosensitivity to particular drugs. To circumvent this problem, many groups are now
trying to derive genomic or transcriptomic signatures that predict the response of tumours to
classic chemotherapy. The p53 gene is a prime candidate for inclusion in these signatures. It
mediates checkpoint or stress responses to a multitude of insults and suppresses tumour
formation through multiple mechanisms including apoptosis, senescence and autophagy.1
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In the late 1990s, preclinical models suggested that breast tumours with mutant p53 would
be resistant to anthracyclines 2, 3 but show similar 4 or increased sensitivity to taxanes.5 To
test the working hypothesis that patients with p53-mutant breast tumours would benefit
preferentially from treatment with taxanes, we initiated a clinical trial in patients with large
operable, locally advanced or inflammatory breast cancer. When designing the trial we took
two important methodological decisions. First, we used a “marker strategy design” so that, if
positive, the result would qualify as biomarker level I evidence, as defined by the American
Society of Clinical Oncology Tumor Marker Guidelines Committee at that time. 6 Second,
to assess p53 status we used a functional assay in yeast (figure 1). 7, 8 This assay detects
biologically important mutations that inactivate p53 as a transcription factor but not silent
mutations or polymorphisms. In practice, immunohistochemistry lacks sensitivity and
specificity, and the functional assay is more sensitive than conventional techniques such as
sequencing, mainly because the assay is insensitive to contamination of samples with normal
tissue. 9, 10 Tumours were biopsied for p53 assessment and patients then received
neoadjuvant therapy with standard anthracycline-based regimen, or with a regimen
containing docetaxel. We report here the final analysis of this clinical trial.
Methods
Study design
This intergroup multicentre phase III trial was performed in 42 centres across nine countries.
The trial was approved by national ethics committees and local ethics committees in all
participating centers. The study is registered in ClinicalTrials.gov, number NCT00017095.
The full protocol can be assessed at http://www.cancer.gov/clinicaltrials/EORTC-10994.
Before registration, all patients gave signed informed consent for the clinical trial and for
research on tumour samples taken before randomisation. A frozen tumour sample was
mandatory before inclusion in the trial (either one incisional biopsy or two trucut biopsies
taken with a 14G needle). Patients eligible for the trial were women aged less than 71 years
with histologically proven invasive carcinoma of the breast suitable for neoadjuvant
chemotherapy. Eligible patients had large operable or locally advanced or inflammatory
breast cancers, defined as T4a,b,c,d any N; or, any clinical T, N2 or N3; or, large T2 or T3;
all were M0 and WHO performance status 0–1. Exclusion criteria are listed in the
supplementary information.
Randomisation and masking
In this open label study, randomisation was performed by an inhouse software at the
EORTC Headquarters, using a minimization method 11 that stratified by institution and
initial tumour stage (large operable versus locally advanced or inflammatory breast cancer).
Patients were randomised in a 1:1 ratio to a standard anthracycline regimen (arm A: 5-
fluorouracil, epirubicin and cyclophosphamide) or a taxane-based regimen (arm B: three
cycles of docetaxel followed by three cycles of docetaxel plus epirubicin). The randomised
arm was only calculated and released to the investigator at the time all eligibility criteria
were confirmed.
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Treatment
In arm A, the nine centers from the Swedish group used tailored FEC; the other centers used
FEC100 (the list of centers is given in the Web Appendix). In arm B, we chose to give
docetaxel as a single agent upfront for three cycles followed by epirubicin and docetaxel
(ET) in combination for three cycles. This approach allowed us to test optimally the
hypothesis that p53-mutant tumours are sensitive to taxanes and resistant to anthracyclines,
without putting patients at risk of undertreatment. For more details of the chemotherapy
regimens see figure 2 and the supplementary methods online. 12–14 At completion of
chemotherapy, in the absence of progression, locoregional treatment was planned according
to the guidelines described in the protocol. Adjuvant endocrine therapy for 5 years after the
end of neoadjuvant chemotherapy was mandatory for women with estrogen receptor (ER)
positive or progesterone receptor (PgR) positive tumours. Aromatase inhibitors were used in
accordance with local, regional or network policy (this information was registered in a
follow-up form). Patients with human epidermal growth factor receptor-2 (HER2) positive
tumours were allowed to enter adjuvant clinical trials assessing trastuzumab or to receive
this treatment in the adjuvant setting when it became standard practice.
p53 assessment
p53 status was tested at the Swiss Institute for Experimental Cancer Research (ISREC) by
yeast functional assay (figure 1) on biopsies that contained ≥20% tumour cells, as previously
described, 7, 8, 15 and in the supplementary file online (appendix section 3). To confirm that
red colonies contained clonal mutations, plasmids were rescued from red yeast colonies
from the first 50 cases scored as mutant. At least four different yeast colonies (clones) were
tested for each case. To estimate the positive and negative predictive value, the distribution
of % red colonies was decomposed into three peaks by fitting a mixture of normal
distributions with the mix function in the mixdist library in the R programming language.
This function is based on maximum likelihood estimation using a combination of a Newton-
type algorithm and the EM algorithm (for details see the Mix Home page: http://
www.math.mcmaster.ca/peter/mix/mix.html).
Statistics
The primary endpoint of the study was progression-free survival, defined as time from
randomisation to progression on neoadjuvant chemotherapy, locoregional relapse (invasive
cancer), first distant metastasis, death from any cause, or invasive contralateral breast
cancer. We did not consider as a primary event: second primary invasive cancer (non
breast), or ipsilateral or contralateral ductal or lobular carcinoma in situ. Patients without an
event were censored at their last follow-up date. Secondary end-points were: distant
metastasis-free survival (time from randomisation to distant progression on neoadjuvant
chemotherapy, first distant metastasis, death from any cause), overall survival (time from
randomisation to death from any cause), clinical response (according to RECIST criteria),16
pathological response (complete pathological response was defined as complete
disappearance of any invasive cancer in the primary tumour with the exception of very few
scattered tumour cells left), and toxicity according to National Cancer Institute Common
Toxicity Criteria version 2.0.17
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The primary objective was to evaluate whether the benefit from the taxane-based arm was
essentially restricted to the p53 mutated group. Three co-primary comparisons of
progression-free survival between treatment arms were planned: in the patients with p53
wild type tumours; in the patients with p53-mutated tumours; and in all randomised patients.
Each primary test was a two-sided log rank test stratified for corrected stage of disease
(locally advanced vs. large operable) at 2% alpha error, ensuring an overall 5% alpha error
for these correlated co-primary tests. The final test in the p53 mutated group was at a
nominal 1.4% alpha error, ensuring experiment-wise 2% alpha level after a per protocol
interim analysis at 66% of the required events in this group. Because of the correction for
multiplicity, the confidence intervals, although calculated at 98%, are to be interpreted as
95% confidence intervals (experimentwise). The P-values for the 3 primary tests need to be
compared to the critical level of 0.02.
The trial was designed to have 80% power to detect hazard ratios of respectively 0.72, 0.67
and 0.80 in the p53 wild type group, the p53 mutated group, and the full sample. This was
assuming an overall accrual of 1850 patients followed for an additional 2.5 years after end
of accrual, a 15% non assessibility rate for p53, and a 2:1 ratio between wild type and
mutated in those assessable.
For further details of the sample size calculation and planned statistical analyses, see the
supplementary Methods online. This analysis is based on the final database lock performed
on 24 February 2010. All of the analyses were performed on an intention-to-treat basis. Up
to May 2009 we observed that there were fewer events than anticipated and that the
proportion of p53 wild type tumours was lower than anticipated. As a result, the power of
the comparison in the p53 wild type group was compromised. To resolve this problem we
sought the advice of an external independent committee. They recommended to carry out the
final analysis once the planned 270 events were confirmed in the p53 mutated group. This
would ensure that the main goal of the study was met with the planned power (80% power to
detect a progression-free survival difference between the arms when p53 was mutant). They
recommended to carry out the other planned analyses (overall, p53 wt group and interaction
test) at the same time, while acknowledging that these comparisons would be slightly
underpowered. Following this recommendation, the clinical cut-off date used was 1
December 2009 after the threshold value of 270 primary endpoint events in the p53 mutated
group was met.
Unless otherwise mentioned, all analyses were run in SAS version 9.2. The clinical database
resides at EORTC.
Role of the funding source
The sponsor of the trial (EORTC) designed and coordinated the trial. The funding sources of
the study had no role in the design of the study; collection, analysis, or interpretation of the
data; or in the writing of this report. JB had full access to the raw data. The corresponding
author had the final responsibility to submit for publication.
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Results
From 25 April 2001 to 20 November 2006, 1856 patients were included; 928 were randomly
assigned to the FEC regimen and 928 to the T-ET regimen. The median length of follow-up
at the time of database lock was 57 months (quartiles 44 and 70 months, IQR 26 months).
Baseline characteristics and treatment
In the entire series, 1429 patients (77%) presented with large operable tumours, 1194 were
ER positive (64%), and 451 were HER2 positive (28%) (table 1). Surgery was performed
after neoadjuvant treatment in 1809 patients (97.5%) of whom 764 (42.2%) underwent
conservative treatment. Of 1241 patients with ER or PgR positive tumours 1192 (96%)
received adjuvant endocrine therapy. Among 451 patients with HER2 positive tumours, only
142 (32%) received adjuvant trastuzumab because this treatment was not yet standard during
most of the recruitment period. The compliance with allocated treatment and details on
treatment discontinuation are given on the CONSORT diagram (figure 2). Of the 1856
patients enrolled, 22 patients (1.1%) were ineligible and 370 (20%) were unassessable for
p53 tumour status (including 6 for both reasons) (figure 3). The main reason was samples
with less than 20% tumour cells. These samples were excluded because the normal cells in
the sample would have generated a false negative result; they were not technical failures of
the yeast assay as such. The characteristics of this group of patients are very similar to the 2
other groups (p53 wild type and mutated) (supplementary table 1).
p53 functional assay
The p53 test was performed on tumour biopsies from 1486 patients (80%) and failed in 17
patients (1.1%) (figure 3). Taking into account all technical reasons, the p53 test was either
not performed (370) or failed (17) in 20.9% of cases (figure 3). Tumours from 825 patients
were classified as wild type (56.2%) and from 644 patients as mutated (43.8%). The p53
functional assay tests whether p53 is able to activate transcription of a reporter gene in yeast
(figure 1). The percentage of red colonies in the yeast assay reflects the relative abundance
of wild type and mutant p53 mRNA in the sample. Figure 4 shows the observed distribution
of the % red colonies for the 1469 patients for whom the assay was successful. The positive
predictive value (PPV) and negative predictive value (NPV) of the assay can be estimated
by decomposing the distribution into its three constituent peaks as shown in figure 4: false
positives are in the tail of the wild type distribution above the 20% cut-off; false negatives
are in the tail of the “heterozygous” distribution below the 20% cut-off. Analysed in this
way, the PPV is estimated as 99% and the NPV as 92%.
Progression-free survival
By the time of analysis, 675 events for the primary endpoint had occurred (table 2). Of these
522 (77%) were distant recurrences. The three co-primary comparisons of progression-free
survival between the FEC and T-ET arms were performed in the p53 mutant group, the p53
wild type group, and the whole population. No significant difference between the 2 arms
was found at the predefined p-values (respectively, 0.014, 0.02 and 0.02; figure 5a). In the
p53 mutant group, the HR was 0.84 in favour of T-ET (98.6% CI: 0.63–1.14; log-rank test
stratified for stage: p = 0.17). The 5-year progression-free survival rates were 59.5% (95%
Bonnefoi et al. Page 6
Lancet Oncol. Author manuscript; available in PMC 2014 September 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
CI: 53.4–65.1) in the T-ET arm and 55.3% (95% CI: 49.2–60.9) in the FEC arm. In the p53
type wild group, the HR was 0.89 in favour of T-ET (98% CI: 0.68–1.18; log-rank test
stratified for stage: p = 0.35). The 5-year progression-free survival rates were 66.8% (95%
CI: 61.4–71.6) in the T-ET arm and 64.7% (95% CI: 59.6–69.4) in the FEC arm. In the
whole population, the HR in favour of T-ET was 0.85 (98% CI: 0.71–1.02; log-rank test
stratified for stage: p = 0.035). The 5-year progression-free survival rates were 65.1% (95%
CI: 61.6–68.3) in the T-ET arm and 60.8% (95% CI: 57.3–64.2) in the FEC arm. There was
no evidence of an interaction between p53 status and treatment arm (p = 0.68).
Overall survival and distant metastasis-free survival
By the time of analysis, 351 patients (19%) had died. None of the three comparisons for
overall survival was significant at the predefined significance level (p = 0.02). Distant
metastasis-free survival was similar to progression-free survival because three quarters of
the first progression-free survival events were distant metastases. The overall survival and
distant metastasis-free survival curves, with their respective HRs, confidence intervals and
p-values, are shown in figures 5b and supplementary figure 1.
Complete clinical response and complete pathological response
For both complete clinical response and complete pathological response, we compared
treatment arms for all randomised patients, for patients with p53 wild type tumours, and for
patients with p53 mutant tumours. For clinical complete response and complete pathological
response none of the comparisons reached significance at the 0.02 level (table 3). The
pathological complete response rates were respectively 23.5% in the FEC arm and 26.5% in
the taxane arm. There was no evidence for an interaction between p53 status, chemotherapy
regimen and response to treatment (p = 0.75).
Multivariate analyses
In the first model for progression-free survival and overall survival we used clinical and
pathological variables. For progression-free survival, most of the covariates were significant
in the univariate models, but only five were retained after backward selection in the
multivariate analysis: grade, clinical tumour size (cT), clinical nodal status (cN), endocrine
treatment and performance status (table 4). Many factors selected in the univariate model are
known to be highly correlated and for this reason were rejected from the multivariate model.
For overall survival, the vast majority of the variables were also significant in the univariate
analysis but only five were retained in the multivariate analysis : p53 status, cT, cN,
endocrine treatment and performance status (table 4). The PFS and OS of patients
unassessable for p53 tumour status appear similar to the p53 wild type group (in the
univariate analysis HR 1.04 and 1.10 respectively) (table 4).
In the second multivariate model we added to the factors used in the first analysis three
additional groups, named “simplified subtypes”, based on hormone receptor and HER2
status: triple negative tumours (ER, PgR and HER2 negative), HER2 positive tumours (and
ER and PgR known) and other (all other cases with the three factors known). To explore the
role of p53 in these subtypes, we performed univariate and multivariate analyses in a subset
of 1422 patients for whom full data were available (table 5). In the analysis for progression-
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free survival, “subtype” was not kept as a covariate and thus does not add anything to the
first analysis. In the multivariate analysis for overall survival, four variables were retained:
p53, cT, cN, and subtype.
Comparison within subgroups for progression-free survival
The treatment effect was broadly similar among all subgroups defined by common clinical
characteristics (stage, age, menopausal status post chemotherapy), choice of control regimen
(FEC100 or tailored FEC), biological markers (p53 status, endocrine sensitivity, HER2
status) and “simplified subtypes”, with the possible exception of triple negatives (figure 6
and supplementary figure 2). The outcome of tailored FEC and FEC100 was similar (the
HRs in favor of T-ET were 0.91 and 0.83 respectively).
Toxicity
As expected from the literature on similar regimens, the toxicity profile of the 2 arms were
dissimilar, but not different from what has been previously published. We observed a higher
frequency of febrile neutropenia and grade 3/4 infection with T-ET arm and a higher
frequency of grade 3/4 vomiting in the FEC arm (table 6). Two patients died of toxicity
during or within 30 days of chemotherapy completion and without disease relapse: 1 in each
arm (table 2).
Discussion
To the best of our knowledge this is the first large prospective clinical trial explicitly
designed to assess the ability of a biological marker to predict the response of tumours to
different chemotherapy regimens. The interest in identifying predictive markers for classic
chemotherapy derives from the hypothesis that only a subgroup of tumours is genetically
programmed to respond well to particular drugs. The main conclusion of this trial is that
tumour p53 status, defined by a yeast functional assay, can not be used to identify a
subgroup of patients more likely to benefit from chemotherapy regimens containing taxanes.
There are several possible explanations for the negative result of the trial. One is that the
trial may have been underpowered to reach the particularly stringent significance limits (α =
0.02) we were forced to adopt to accommodate the three primary endpoints. This explains
why the overall difference was deemed not to be statistically significant despite the
estimated proportional risk reduction being similar to that seen in PACS01, a Franco-
Belgian adjuvant trial with similar regimens (15% at p = 0.035 in EORTC 10994 versus
17% in PACS01).12 The trial may also have been underpowered if the benefit of taxanes in
the p53 mutant group was smaller than expected under our hypothesis. In daily practice,
only a large effect would be clinically relevant, so it would be difficult to justify performing
a much larger trial to confirm the weak trend observed in this study.
The second possibility is that the yeast functional assay did not properly assess p53 status. It
might be argued that this study would have been positive if we had used another technique,
such as DNA sequencing, to identify p53 mutations. We consider this unlikely because the
high p53 mutation rate in this study (44%) is consistent with other reports in breast cancer
that used the yeast assay,18–20 and it is higher than most reports based on DNA
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sequencing.21–24 Sequencing the entire p53 locus from samples microdissected to remove
normal tissue could be considered a gold standard for detecting p53 mutations, but it is too
technically demanding for use in a routine setting. In our experience the yeast assay is
consistently the most sensitive simple technique for detecting p53 mutations.9, 10 Given this
high sensitivity, other methods to assess p53 status have to be considered even less
promising in predicting taxane response. There are multiple reasons for the high sensitivity
of the yeast assay25, but the most important is probably the ability to detect mutations in the
presence of normal tissue. Because of this we were able to accept samples into the study
with only 20% tumour cells. To confirm that the assay was detecting genuine p53 mutations,
rather than technical artefacts such as PCR splicing or vector self-ligation,8 we sequenced
p53 from red yeast colonies for the first 50 cases scored as mutant. We identified clonal
mutations in every case (supplementary table 2). In addition to false negatives intrinsic to all
cDNA-based approaches, such as deletions that remove the promoter or the entire locus,
there are several additional potential sources of error. Firstly, p53 uses alternative promoters,
alternative splicing and alternative translation start sites, resulting in the expression of a
large array of different isoforms, some of which are not detected in the yeast assay.26–28
Secondly, the yeast assay does not distinguish pure loss-of-function mutants from mutants
with simultaneous gain and loss of function, so we might have missed a gain-of-function
effect.14, 29, 30 To explore this point we have embarked on a DNA sequencing study. Finally,
the yeast assay does not detect mutation or silencing of other genes in the p53 pathway, such
as MDM2, ARF and miR-34a.1 Taken together, these arguments all point to the p53
pathway being inactivated in a much higher proportion of breast tumours than is generally
assumed.
A third possibility is that our hypothesis that p53-mutant tumours would be resistant to
anthracyclines but sensitive to taxanes was wrong. The control regimen, FEC, contained
three drugs known to activate wild type p53 strongly3 and was considered at that time to be
one of the best standard regimens. The study design thus assumed that the experimental arm
(T-ET) would be independent of p53 status (because the taxane would still be active in the
p53-mutant group),4, 5 whereas the control arm (FEC) would show reduced activity in the
p53-mutant group. Ironically, over the period the study was recruiting, de Thé and
colleagues published a series of papers that question our assumption that FEC would be a
good control regimen.18–20 Specifically, their results suggest that p53-mutant tumours may
be more sensitive than wild type tumours to high dose anthracycline-
cyclophosphamide.18, 19 They attribute this in particular to the high dose
cyclophosphamide.20 We think this is not relevant to our study because the dose of
cyclophosphamide we used is definitely below that postulated by de Thé to target p53
mutant tumours. The only exception is the Swedish cohort, who received a FEC variant
called tailored FEC that contains a higher dose of cyclophosphamide. We analysed the
response of p53-mutant tumours in this subgroup (supplementary table 3) and saw no
significant difference in progression-free survival (the HR was 0.72 in favour of T-ET).
Notwithstanding the trend in the wrong direction, we can not formally exclude the
possibility that p53-mutant tumours might be hypersensitive to cyclophosphamide because
the small number of p53-mutant tumours in the Swedish cohort (34 treated with FEC, 45
treated with T-ET) means the 95% confidence interval for the hazard ratio includes HR=1.
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Several gene signatures have been published that predict p53 status in breast cancer.19, 31
The genes in these signatures are closely linked to proliferation and ER status. Our study
supports these observations: among patients with data available, 18% of grade I tumours
were p53 mutant versus 62% of grade III tumours; and 32% of ER+ tumours were p53
mutant versus 70% of ER- tumours (supplementary table 1).
Beside p53, there is considerable interest in using hormone receptors and HER2 to predict
the response to taxanes. In the CALGB9344 trial, taxanes were less effective in ER positive
tumours,32 a result not supported by some other studies.33–35 In our trial there was a 20%
reduction in the risk of recurrence in the ER or PgR positive subgroup treated with taxane
(95% CI: 0.66–0.98, figure 6). In addition, when taking in consideration HER2 status, no
benefit of taxanes was found in the ER positive/HER2 negative subgroup in the
CALGB9344 trial,36 whereas in our trial there was a 16% reduction in the risk of
recurrence, albeit with a wide confidence interval (95% CI: 0.64–1.1, supplementary figure
3). A likely explanation for these differences is heterogeneity of the ER positive populations
in the different trials.
Our study shows that predicting the response to conventional chemotherapy is a great deal
more difficult than predicting the response to targeted therapies. This is presumably because
the greatest tumour specificity lies in the oncogenic mutations driving tumour growth, like
bcr-abl translocation or HER2 amplification. Viewed from this perspective, p53 status will
have the greatest predictive value when it is used to select treatments that act on mutant p53
itself or on its immediate partners to relieve blocks to p53 activation. There is now a massive
effort among academic laboratories and the pharmaceutical industry to develop drugs with
exactly these properties, such as drugs that stabilize mutants in the wild type conformation
and drugs that interfere with p53 degradation.37 Since patients with p53 mutations have a
poor prognosis, there is a clear need for these therapies targeted against mutant or
inactivated forms of p53.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel: research in context
Systematic review
In the late 1990’s when designing this study we did not perform a systematic review. At
that time, p53 had been shown in the NCI60 screen 3 to play a pivotal role in the response
to a large panel of anti-cancer drugs, with the notable exception of anti-microtubule
drugs 3 including taxanes. 4,5 These data suggested that breast tumours with mutant p53
would be resistant to anthracyclines but sensitive to taxanes. Although this was the
dominant view at the time, it was controversial because some studies reported conflicting
results for individual drugs, in particular between mouse and human tumours, or between
different cell lines. The clinical literature could not resolve the issue because it included
only retrospective studies that were unable to distinguish the prognostic value of p53
from its ability to predict the response to chemotherapy. In addition these studies used
mainly immunohistochemistry, which lacks sensitivity and specificity, or various DNA
sequencing techniques, most of which lack sensitivity. We concluded that the only way
to solve these problems would be to perform a prospective clinical trial with a more
sensitive and specific test to detect p53 mutations.
Interpretation
This is the first large prospective clinical trial explicitly designed to assess the ability of
p53 to predict the response of tumours to different chemotherapy regimens. We used a
highly sensitive functional yeast assay. Although p53 status is prognostic for overall
survival, it does not identify patients more likely to benefit from chemotherapy regimens
containing taxanes. Further prospective studies should test the “de Thé hypothesis” 20, or
drugs that act directly on p53 and its partners (for example, nutlin, RITA and PRIMA) 37.
Bonnefoi et al. Page 14
Lancet Oncol. Author manuscript; available in PMC 2014 September 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Outline of the assay
p53 mRNA is extracted from the tumour biopsies, converted to cDNA, and amplified by
PCR. The p53 PCR product is transfected into yeast, where it is cloned into a yeast
expression vector by homologous recombination. Every yeast colony contains the progeny
of a single p53 mRNA. P53 is a transcription factor. When wild type p53 protein is
expressed within the yeast cell, it binds to a p53 binding site in a p53 responsive promoter in
an ADE2 reporter gene and activates expression of Ade2 protein. Mutant p53 is unable to
bind to DNA and fails to induce Ade2 expression. Yeast containing Ade2 protein form white
colonies. Yeast lacking Ade2 form red colonies.
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Figure 2.
CONSORT diagram
Abbreviations: FEC100: 5-fluorouracil 500mg/m2, epirubicin 100mg/m2, cyclophosphamide
500mg/m2 all intravenously every 21 days for 6 cycles; Tailored FEC: first cycle on day 1
with 5-fluorouracil 600 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 900 mg/m2, all
intravenously every 21 days, with granulocyte colony-stimulating factor (G-CSF) 5 ug/kg on
days 5–12 and ciprofloxacin orally 500 mg twice daily on days 2–15, subsequent cycles
were modified for each individual as previously described for 6 cycles (maximal epirubicin
dose 120 mg/m2/cycle and cyclophosphamide dose 1200 mg/m2/cycle); T-ET: docetaxel
100mg/m2 every 21 days for 3 cycles followed by epirubicin 90mg/m2 and docetaxel
75mg/m2 every 21 days without G-CSF for 3 cycles; pts: patients; CT: chemotherapy.
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Figure 3.
Trial profile
Abbreviations:
(1) Most important reasons for ineligibility (total=22): Clinical : T1, N0–1 = 3; M1 = 6 ;
Psychiatric disorder = 2 ; Inappropriate type of cancer = 2 ; Bilateral BC = 7 ; Prior
treatment not allowed = 1 ; Withdrawn consent = 1
(2) Reasons for inability to include patients in the planned testing (total=370): No sample =
67; Not assessable = 6; Samples that could not be tested because <20% tumour cells = 291
eligible patients and 6 ineligible patients
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Figure 4.
Distribution of the percentage (%) of red colonies
The percentage of red colonies depends on the amount of mutant mRNA in the tumour cells
in the biopsy, the amount of wild type mRNA in the normal cells in the biopsy, and the
background. The distribution is modeled as three peaks. The peak on the left corresponds to
samples containing only wild type p53 (the background in the assay is thus 11% ± 4%; the
main cause is PCR mutations.14 The peak on the right corresponds to tumours with
homozygous p53 mutations (76% ± 14%). The mean wild type p53 mRNA content in the
homozygous group is thus ~27% (24% plus the background). Between the wild type and
homozygous peaks there is a third peak that is best explained by nonsense p53 mutations or
heterozygous (particularly dominant negative) missense p53 mutations, but could potentially
be explained by intra-tumoural heterogeneity, an intense inflammatory infiltrate or a florid
stromal reaction.
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Figure 5.
(a) Progression-free survival and (b) Overall survival in the 3 groups by treatment arm: p53
mutated group, p53 wild type group and all patients
Abbreviations
HR: hazard ratio; 5 yr PFS: 5 year progression-free survival; 5yr OS: 5 year overall survival;
CI: confidence interval; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; T-ET:
docetaxel followed by epirubicin and docetaxel.
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Figure 6.
Hazard ratios for progression-free survival by clinical characteristics, choice of regimen,
biological markers, and simplified subtypes
Abbreviations
LA: locally advanced; LO: large operable; Menop. > CT: menopausal status post
chemotherapy; Miss: missing; ER: estrogen receptor; PgR: progesterone receptor; HER2:
human epidermal growth factor receptor 2; +: positive; −: negative; trip. Neg: triple
negative; T-ET: docetaxel followed by epirubicin and docetaxel; FEC: 5-fluorouracil,
epirubicin, and cyclophosphamide; HR: hazard ratio; CI: confidence interval.
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Table 1
Baseline characteristics, surgery and adjuvant treatment by randomised treatment group
All patients
FEC arm
N=928
N (%)
T-ET arm
N=928
N (%)
Total
N=1856
N (%)
Age Median 48.9 48.6 48.8
Range 22.2 – 70.6 24.0 – 70.9 22.2 – 70.9
≤40 183 (19.7) 192 (20.7) 375 (20.2)
41–50 361 (38.9) 354 (38.1) 715 (38.5)
51–70 384 (41.4) 382 (41.2) 766 (41.3)
Menopausal status Premenoapausal 396 (42.7) 424 (45.7) 820 (44.2)
Postmenopausal 311 (33.5) 290 (31.3) 601 (32.4)
Unknown 221 (23.8) 214 (23.0) 435 (23.4)
Category Ineligible 3 (0.3) 3 (0.3) 6 (0.3)
LocallyAdv./Inflammatory 213 (23.0) 208 (22.4) 421 (22.7)
Large operable 712 (76.7) 717 (77.3) 1 429(77.0)
T stage T1 8 (0.9) 5 (0.5) 13 (0.7)
T2 442 (47.6) 475 (51.2) 917 (49.4)
T3 297 (32.0) 276 (29.7) 573 (30.9)
T4 181 (19.5) 171 (18.4) 352 (19.0)
Tx 0 (0.0) 1 (0.1) 1 (0.1)
N stage N0 399 (43.0) 393 (42.3) 792 (42.7)
N1 455 (49.0) 469 (50.5) 924 (49.8)
N2 61 (6.6) 55 (5.9) 116 (6.3)
N3 11 (1.2) 9 (1.0) 20 (1.1)
Nx 2 (0.2) 2 (0.2) 4 (0.2)
M stage
M0 921 (99.2) 922 (99.4) 1 843(99.3)
M1(*) 7 (0.8) 6 (0.6) 13 (0.7)
Histologic type
Ductal 780 (84.1) 766 (82.5) 1 546 (83.3)
Lobular 96 (10.3) 104 (11.2) 200 (10.8)
Other 47 (5.1) 47 (5.1) 94 (5.1)
Unknown 5 (0.5) 11 (1.2) 16 (0.9)
Grade 1 65 (7.0) 56 (6.0) 121 (6.5)
2 434 (46.8) 425 (45.8) 859 (46.3)
3 298 (32.1) 317 (34.2) 615 (33.1)
Unknown or NA 131 (14.1) 130 (14.0) 261 (14.0)
ER status Negative 283 (30.5) 298 (32.1) 581 (31.3)
Positive 602 (64.9) 592 (63.8) 1 194 (64.3)
Unknown 43 (4.6) 38 (4.1) 81 (4.4)
PgR status Negative 399 (43.0) 379 (40.8) 778 (41.9)
Positive 431 (46.4) 453 (48.8) 884 (47.6)
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All patients
FEC arm
N=928
N (%)
T-ET arm
N=928
N (%)
Total
N=1856
N (%)
Unknown 98 (10.6) 96 (10.3) 194 (10.5)
HER2(†) Positive 230 (29) 221 (27.8) 451 (28.3)
Negative 560 (70.6) 574 (72.1) 1 134(71.4)
Inconclusive 3 (0.4) 1 (0.1) 4 (0.3)
p53 status Not done (‡) or failure 183 (19.7) 204 (22.0) 387 (20.9)
Wild type 427 (46.0) 398 (42.9) 825 (44.5)
Mutant 318 (34.3) 326 (35.1) 644 (34.7)
Surgery performed after neoadjuvant chemotherapy No 15 (1.6) 11 (1.2) 26 (1.4)
Yes 902 (97.2) 907 (97.7) 1809 (97.5)
Missing 11 (1.2) 10 (1.1) 21 (1.1)
If yes, type of surgery Lumpectomy/quadrantectomy 378 (41.9) 386 (42.6) 764 (42.2)
Mastectomy 524 (58.1) 521 (57.4) 1045 (57.8)
Patients with ER and/or PgR positive tumours
N=628 N=613 N=1241
N (%) N (%) N (%)
Any adjuvant endocrine treatment
No 21 (3.3) 7 (1.1) 28 (2.3)
Yes 595 (94.7) 597 (97.4) 1 192 (96.1)
Unknown 12 (1.9) 9 (1.5) 21 (1.7)
Adjuvant aromatase inhibitor
No 261 (41.6) 267 (43.6) 528 (42.5)
Yes 350 (55.7) 331 (54.0) 681 (54.9)
Unknown 17 (2.7) 15 (2.5) 32 (2.6)
HER2-positive patients
N=230 N=221 N=451
N (%) N (%) N (%)
Adjuvant trastuzumab
No 147 (63.9) 154 (69.7) 301 (66.7)
Yes 78 (33.9) 64 (29.0) 142 (31.5)
Unknown 5 (2.2) 3 (1.4) 8 (1.8)
Abbreviations and legend: ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor receptor 2; FEC: 5-
fluorouracil, epirubicin, and cyclophosphamide; T-ET: docetaxel followed by epirubicin and docetaxel;
(*)
In 7/13 patients ipsilateral supraclavicular nodes were the only metastatic site
(†)
 HER2 status was not collected systematically at baseline, but as a result of an amended case report form. This information was obtained for
1589 patients (85.6%), 793 in arm A and 796 in arm B.
(‡)p53 test was not done in 370 cases. The main reason was samples with less than 20% tumour cells. These samples were excluded because the
normal cells in the sample would have generated a false negative result; they were not technical failures as such (figure 3).
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Table 2
First events contributing to progression-free survival
FEC arm (N=361)* T-ET arm (N=314)*
N (%) N (%)
Progression while on neoadjuvant chemotherapy 30 (8.3) 29 (9.2)
Distant recurrence 279 (77.3) 243 (77.4)
Invasive loco-regional recurrence 27 (7.5) 21 (6.7)
Invasive contralateral cancer 12 (3.3) 12 (3.8)
Death without prior report of progression 13 (3.6) 9 (2.9)
 Progression 2 0
 Treatment toxicity‡ 1 1
 Cancer (non-breast) 5 2
 Cardiovascular 1 3
 Other 0 2
 Unknown 4 1
Abbreviations and legend:
FEC: fluorouracil, epirubicin, cyclophosphamide; T-ET: docetaxel followed by epirubicin and docetaxel;
*
Respectively 361 and 314 had a progression-free survival qualifying event
‡
Deaths occuring during chemotherapy or within 30 days of chemotherapy completion and without disease relapse.
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Table 5
Multivariate analysis for overall survival (second model with addition of subgroups defined by hormone
receptor and HER2 status)
HR CI p
p53 wt 1 0.012
mut 1.49 1.11–2.01
missing 1.00 0.68–1.46
cT T1-2 1 <0.0001
T3 2.12 1.55–2.89
T4 3.30 2.36–4.62
cN N 1 <0.0001
N1 1.93 1.42–2.61
N2 2.28 1.42–3.67
N3 5.98 2.66–13.46
Subtype Other 1 <0.0001
HER2 positive 1.22 0.89–1.66
Triple negative 2.10 1.51–2.92
Abbreviations cT: clinical tumour size; cN: clinical nodal status; wt: wild type; mut: mutated; HER2: human epidermal growth factor receptor.
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